As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: December 11, 2012
by Medical XPress:
Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer’s in patients with mild cognitive impairment, according to researchers at Duke Medicine.
The findings, which appear Tuesday, Dec. 11, 2012, in the journal Radiology, provide new insight into how to accurately detect Alzheimer’s before the full onset of the disease. Duke researchers studied three tests – magnetic resonance imaging (MRI), fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET), and cerebrospinal fluid analysis – to determine whether the combination provided more accuracy than each test individually.
The tests were added to routine clinical exams, including neuropsychological testing, currently used to diagnose Alzheimer’s disease. “This study marks the first time these diagnostic tests have been used together to help predict the progression of Alzheimer’s. If you use all three biomarkers, you get a benefit above that of the pencil-and-paper neuropsychological tests used by doctors today,” said Jeffrey Petrella, MD, associate professor of radiology at Duke Medicine and study author. “Each of these tests adds new information by looking at Alzheimer’s from a different angle.”
Alzheimer’s disease affects more than 30 million people worldwide, and the number is expected to triple by 2050. Research suggests that Alzheimer’s begins years to decades before it is diagnosed, with patients experiencing a phase with some memory loss, or mild cognitive impairment, before the disease’s full onset.
Patients with mild cognitive impairment are at a higher risk for having Alzheimer’s, but not everyone will progress to developing the disease. While there is no cure for Alzheimer’s, new treatments under study are likely to be most effective at the disease’s earliest stages.
Researchers are working to improve early detection of Alzheimer’s, even before patients experience symptoms, but the disease remains difficult to diagnose and patients are often misclassified. “Misdiagnosis in very early stages of Alzheimer’s is a significant problem, as there are more than 100 conditions that can mimic the disease. In people with mild memory complaints, our accuracy is barely better than chance. Given that the definitive gold standard for diagnosing Alzheimer’s is autopsy, we need a better way to look into the brain,” said P. Murali Doraiswamy, MBBS, professor of psychiatry and medicine at Duke and study author.
Dementia is a progressively debilitating neurodegenerative condition. Early intervention and reducing its development by identifying its risk factors are the main goals in dementia treatment. This is particularly important as there is little...
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer’s disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, has...
Sometimes, the hardest part of living with a mental illness isn’t the symptoms, or the management — it’s dealing with stigma from other people. And unfortunately, many people who live with mental illness face stigma...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.